Ziarco Picks Up Pfizer Assets, Series A Round
This article was originally published in The Pink Sheet Daily
A former Pfizer VP used four of the pharma’s programs to secure private financing from an unlikely investor and got the pharma to buy into the new start-up. Now, he hopes to develop next generation treatments for inflammatory and allergic diseases.
You may also be interested in...
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.
At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.
Start-ups raised a total of $670.3 million across all industries in Q4 2012, just $11.6 million less than in Q3, and 90% of that money went to biopharma companies. Several start-up companies inked deals with Big Pharmas, and there were three acquisitions – two in biopharma and one in the device sector.